News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,623 Results
Type
Article (44319)
Company Profile (311)
Press Release (706975)
Multimedia
Podcasts (131)
Webinars (22)
Section
Business (211194)
Career Advice (2116)
Deals (36824)
Drug Delivery (144)
Drug Development (83585)
Employer Resources (176)
FDA (16932)
Job Trends (15540)
News (357866)
Policy (34153)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2641)
Accelerated approval (48)
Adcomms (29)
Allergies (177)
Alliances (51589)
ALS (216)
Alzheimer's disease (1824)
Antibody-drug conjugate (ADC) (473)
Approvals (17321)
Artificial intelligence (700)
Autoimmune disease (300)
Automation (57)
Bankruptcy (373)
Best Places to Work (11768)
BIOSECURE Act (21)
Biosimilars (229)
Biotechnology (184)
Bladder cancer (197)
Brain cancer (76)
Breast cancer (768)
Cancer (5964)
Cardiovascular disease (492)
Career advice (1804)
Career pathing (44)
CAR-T (338)
CDC (60)
Celiac Disease (3)
Cell therapy (925)
Cervical cancer (47)
Clinical research (72530)
Collaboration (2138)
Company closure (5)
Compensation (1417)
Complete response letters (88)
COVID-19 (2817)
CRISPR (114)
C-suite (1173)
Cystic fibrosis (157)
Data (8057)
Decentralized trials (3)
Denatured (39)
Depression (166)
Dermatology (87)
Diabetes (597)
Diagnostics (7030)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (335)
Drug pricing (220)
Drug shortages (34)
Duchenne muscular dystrophy (289)
Earnings (93881)
Editorial (70)
Employer branding (21)
Employer resources (155)
Events (122655)
Executive appointments (1115)
FDA (20728)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1755)
Gene editing (241)
Generative AI (59)
Gene therapy (748)
GLP-1 (1121)
Government (4879)
Grass and pollen (7)
Guidances (409)
Healthcare (19203)
HIV (80)
Huntington's disease (57)
IgA nephropathy (99)
Immunology and inflammation (303)
Immuno-oncology (96)
Indications (197)
Infectious disease (3161)
Inflammatory bowel disease (224)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (297)
Interviews (330)
IPO (16948)
IRA (57)
Job creations (4074)
Job search strategy (1501)
JPM (65)
Kidney cancer (19)
Labor market (102)
Layoffs (593)
Leadership (42)
Legal (8427)
Liver cancer (101)
Longevity (33)
Lung cancer (784)
Lymphoma (434)
Machine learning (62)
Management (60)
Manufacturing (1093)
MASH (198)
Medical device (14030)
Medtech (14158)
Mergers & acquisitions (21134)
Metabolic disorders (1568)
mRNA (222)
Multiple sclerosis (189)
NASH (18)
Neurodegenerative disease (428)
Neuropsychiatric disorders (109)
Neuroscience (3377)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4578)
Now hiring (78)
Obesity (745)
Opinion (315)
Ovarian cancer (228)
Pain (276)
Pancreatic cancer (310)
Parkinson's disease (366)
Partnered (34)
Patents (609)
Patient recruitment (682)
Peanut (65)
People (61675)
Pharmaceutical (84)
Pharmacy benefit managers (34)
Phase 1 (22509)
Phase 2 (31926)
Phase 3 (23885)
Pipeline (8981)
Policy (338)
Postmarket research (2660)
Preclinical (9613)
Press Release (68)
Prostate cancer (310)
Psychedelics (57)
Radiopharmaceuticals (334)
Rare diseases (1121)
Real estate (6323)
Recruiting (72)
Regulatory (26361)
Reports (57)
Research institute (2464)
Resumes & cover letters (362)
Rett syndrome (39)
RNA editing (24)
RSV (88)
Schizophrenia (187)
Series A (295)
Series B (217)
Service/supplier (11)
Sickle cell disease (115)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (49)
Startups (3792)
State (2)
Stomach cancer (19)
Supply chain (130)
Tariffs (99)
The Weekly (90)
Vaccines (1129)
Venture capital (112)
Weight loss (490)
Women's health (129)
Worklife (20)
Date
Last 7 days (685)
Last 30 days (3328)
Last 365 days (30527)
2026 (13284)
2025 (30689)
2024 (35760)
2023 (40627)
2022 (51798)
2021 (56326)
2020 (54789)
2019 (47397)
2018 (35767)
2017 (33135)
2016 (32661)
2015 (38614)
2014 (32516)
2013 (27632)
2012 (29731)
2011 (30488)
2010 (28497)
Location
Africa (807)
Alabama (93)
Alaska (7)
Arizona (357)
Arkansas (16)
Asia (42648)
Australia (6851)
California (13469)
Canada (3823)
China (1403)
Colorado (572)
Connecticut (582)
Delaware (416)
Europe (91842)
Florida (2017)
Georgia (430)
Hawaii (3)
Idaho (62)
Illinois (1078)
India (93)
Indiana (613)
Iowa (23)
Japan (554)
Kansas (133)
Kentucky (50)
Louisiana (44)
Maine (76)
Maryland (1610)
Massachusetts (9650)
Michigan (369)
Minnesota (732)
Mississippi (6)
Missouri (145)
Montana (33)
Nebraska (29)
Nevada (144)
New Hampshire (84)
New Jersey (3533)
New Mexico (30)
New York (3522)
North Carolina (1724)
North Dakota (9)
Northern California (6752)
Ohio (401)
Oklahoma (24)
Oregon (46)
Pennsylvania (2710)
Puerto Rico (29)
Rhode Island (50)
South America (1180)
South Carolina (87)
South Dakota (2)
Southern California (5318)
Tennessee (214)
Texas (2145)
United States (47589)
Utah (401)
Vermont (1)
Virginia (339)
Washington D.C. (80)
Washington State (1076)
West Virginia (4)
Wisconsin (135)
Wyoming (2)
751,623 Results for "amylin pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act
Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t have a chance for one key reason.
April 30, 2026
·
2 min read
·
Annalee Armstrong
Obesity
Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.
April 23, 2026
·
2 min read
·
Tristan Manalac
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
April 29, 2026
·
6 min read
Press Releases
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
April 28, 2026
·
4 min read
Press Releases
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
April 7, 2026
·
4 min read
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
March 6, 2026
·
3 min read
·
Tristan Manalac
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
February 6, 2026
·
4 min read
·
Mark Zipkin
Press Releases
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
February 11, 2026
·
4 min read
Press Releases
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
March 5, 2026
·
7 min read
1 of 75,163
Next
